Recent advances in multiple myeloma

Current Opinion in Hematology

Volumn 7, Issue 4, 2000, Pages 241-246

  Sjak Shie, Nelida N ^a   Vescio, Robert A ^a,b   Berenson, James R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; THALIDOMIDE;

ANGIOGENESIS; BONE MARROW TRANSPLANTATION; CANCER CYTODIAGNOSIS; CYTOGENETICS; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN TISSUE; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; CYTOKINES; DIPHOSPHONATES; GROWTH SUBSTANCES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOLYSIS; PLASMA CELLS; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE;

EID: 0034092245     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200007000-00007     Document Type: Review

References (75)

1. 1 Rettig MB, Ma HJ, Vescio RA, et al.: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients [comments]. Science 1997, 276:1851-1854.
2. 2 Said JW, Rettig MR, Heppner K, et al.: Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma [comments]. Blood 1997, 90:4278-4282.
3. 3 Rask C, Kelsen J, Olesen G, et al.: Danish patients with untreated multiple myeloma do not harbour human herpesvirus 8. Br J Haematol 2000, 108:96-98.
4. 4 Bellos F, Goldschmidt H, Dorner M, et al.: Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA. Ann Oncol 1999, 10:323-327.
5. 5 Chauhan D, Bharti A, Raje N, et al.: Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood 1999, 93:1482-1486.
6. 6 Brousset P, Meggetto F, Laharrague P, et al.: Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow biopsy from patients with multiple myeloma: PCR amplification of orf26 but not orf72 and orf75 sequences [letter]. Br J Haematol 2000, 108:197-198.
7. 7 Raje N, Gong J, Chauhan D, et al.: Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 1999, 93:1487-1495.
8. 8 Belec L, Mohamed AS, Authier FJ, et al.: Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 1999, 93:3643-3653.
9. 9 Vescio RA, Wu CH, Zheng L, et al.: Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients. Bone Marrow Transplant 2000, 25:153-160.
10. 10 Sjak-Shie NN, Vescio RA, Berenson JR: The role of human herpesvirus-B in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999, 13:1159-1167.
11. 11 MacKenzie J, Sheldon J, Morgan G, et al.: HHV-8 and multiple myeloma in the UK [letter]. Lancet 1997, 350:1144-1145.
12. 12 Gao SJ, Alsina M, Deng JH, et al.: Antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma. J Infect Dis 1998, 178:846-849.
13. 13 Drach J, Schuster J, Nowotny H, et al.: Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995, 55:3854-3859.
14. 14 Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al.: Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998, 91:3366-3371.
15. 15 Avet-Loiseau H, Li JY, Facon T, et al.: High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998, 58:5640-5645. This well executed study examines the incidence of illegitimate immunoglobulin heavy chain rearrangements in myeloma using FISH.
16. 16 Avet-Loiseau H, Brigaudeau C, Morineau N, et al.: High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosom Cancer 1999, 24:9-15.
17. 17 Seong C, Delasalle K, Hayes K, et al.: Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998, 101:189-194.
18. 18 Avet-Loiseau H, Li JY, Morineau N, et al.: Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 1999, 94:2583-2589.
19. 19 Vacca A, Ribatti D, Presta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
20. 20 Bellamy WT, Richter L, Frutiger Y, et al.: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
21. 21 Ribatti D, Vacca A, Nico B, et al.: Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999, 79:451-455.
22. 22 Munshi N, Wilson CS, Penn J, et al.: Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies [abstract]. Blood 1998, 92.
23. 23 Rajkumar SV, Fonseca R, Witzig TE, et al.: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999, 13:469-472.
24. 24 Klein B, Zhang XG, Lu ZY, et al.: Interleukin-6 in human multiple myeloma. Blood 1995, 85:863-872.
25. 25 Chauhan D, Pandey P, Ogata A, et al.: Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP klnase independent mechanism. Oncogene 1997, 15:837-843.
26. 26 Xu FH, Sharma S, Gardner A, et al.: Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood 1998, 92:241-251.
27. 27 Bataille R, Barlogie B, Lu ZY, et al.: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691.
28. 28 Cozzolino F, Torcia M, Aldinucci D, et al.: Production of interleukin-1 by bone marrow myeloma cells. Blood 1989, 74:380-387.
29. 29 Carter A, Merchav S, Silvian-Draxler I, et al.: The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990, 74:424-431.
30. 30 Donovan KA, Lacy MQ, Kline MP, et al.: Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 1998, 12:593-600.
31. 31 Lacy MQ, Donovan KA, Heimbach JK, et al.: Comparison of interleukin-1 β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999, 93:300-305.
32. 32 Jourdan M, Tarte K, Legouffe E, et al.: Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999, 10:65-70.
33. 33 Filella X, Blade J, Guillermo AL, et al.: Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev 1996, 20:52-56.
34. 34 Filella X, Blade J, Montoto S, et al.: Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma. Cytokine 1998, 10:993-996.
35. 35 Jelinek DF, Witzig TE, Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997, 159:487-496.
36. 36 Georgii-Hemming P, Wiklund HJ, Ljunggren O, et al.: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996, 88:2250-2258.
37. 37 Jelinek DF: Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 1999, 13:1145-1157.
38. 38 Xu F, Gardner A, Tu Y, et al.: Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 1997, 97:429-440.
39. 39 Vanderkerken K, Asosingh K, Braet F, et al.: Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999, 93:235-241.
40. 40 Klein B, Lu ZY, Gu ZJ, et al.: Interleukin-10 and Gp130 cytokines in human multiple myeloma. Leuk Lymphoma 1999, 34:63-70.
41. 41 Borset M, Seidel C, Hjorth-Hansen H, et al.: The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 1999, 32:249-256.
42. 42 Hjertner O, Torgersen ML, Seidel C, et al.: Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94:3883-3888. This paper proposes a potential mechanism underlying myeloma bone resorption that involves plasma cells, osteoblasts, and osteoclasts.
43. 43 Romas E, Udagawa N, Zhou H, et al.: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med 1996, 183:2581-2591.
44. 44 Hughes FJ, Howells GL: Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int 1993, 53:362-364.
45. 45 van Hoeven KH, Reed LJ, Factor SM: Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy. Cancer 1990, 66:1472-1474.
46. 46 Hjorth M, Hellquist L, Holmberg E, et al.: Initial versus deferred melphalanprednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993, 50:95-102.
47. 47 Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832-3842. This is an excellent meta-analysis of all major clinical trials comparing melphalan-prednisone with other chemotherapy combinations.
48. 48 Alexanian R, Dimopoulos MA, Delasalle K, et al.: Primary dexamethasone treatment in multiple myeloma. Blood 1992, 80:887-890.
49. 49 Ludwig H, Cohen AM, Polliack A, et al.: Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995, 6:467-476.
50. 50 Tura S, Cavo M: Allogeneic bone marrow transplantation in multiple myeloma. Hematol Oncol Clin N Am 1992, 6:425-435.
51. 51 Gahrton G: Allogeneic bone marrow transplantation in multiple myeloma. Pathol Biol (Paris) 1999, 47:188-191. This is a good review of the role of allogeneic transplantation in myeloma.
52. 52 Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
53. 53 Gahrton G, Svensson H, Bjorkstrand B, et al.: Syngeneic transplantation in multiple myeloma: a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999, 24:741-745.
54. 54 Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [comments]. N Engl J Med 1996, 335:91-97.
55. 55 Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997, 34:61-66.
56. 56 Lenhoff S, Hjorth M, Holmberg E, et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000, 95:7-11.
57. 57 Palumbo A, Triolo S, Argentino C, et al.: Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999, 94:1248-1253.
58. 58 Fermand JP, Ravaud P, Chevret S, et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
59. 59 Siegel DS, Desikan KR, Mehta J, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999, 93:51-54.
60. 60 Vesole DH: Bone marrow and stem cell transplantation for multiple myeloma. Cancer Treat Res 1999, 99:171-194.
61. 61 Fermand JP, Brechignac S: The role of autologous stem cell transplantation in the management of multiple myeloma. Pathol Biol (Paris) 1999, 47:199-202.
62. 62 Tribalto M, Amadori S, Cudillo L, et al.: Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study [in process citation]. Haematologica 2000, 85:52-58.
63. 63 Gupta D, Bybee A, Cooke F, et al.: CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999, 104:166-177.
64. 64 Vescio R, Berenson J: Autologous transplantation: purging and the impact of minimal residual disease. Hematol Oncol Clin North Am 1999, 13:969-986.
65. 65 Berenson JR, Crowley J, Barlogie B, et al.: Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients [abstract]. Blood 1998, 92. This paper suggests that maintenance therapy with oral steroids is well tolerated and prolongs survival in myeloma patients.
66. 66 Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma [comments]. N Engl J Med 1999, 341:1565-1571. This is the first large study to demonstrate clinical benefit of thalidomide when used in patients with chemotherapy-refractory myeloma.
67. 67 Larkin M: Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 1999, 354:925.
68. 68 Munshi N, Desikan R, Zngari M, et al.: Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM) [abstract]. Blood 1999, 94.
69. 69 Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments]. N Engl J Med 1996, 334:488-493.
70. 70 Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group [see comments]. J Clin Oncol 1998, 16:593-602.
71. 71 Fontana A, Hernmann Z, Menssen HD, et al.: Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma [abstract]. Blood 1998, 92.
72. 72 Dallas SL, Garrett IR, Oyajobi BO, et al.: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697-1706.
73. 73 Coleman RE, Purohit OP, Black C, et al.: Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999, 10:311-316.
74. 74 Lipton A, Berenson JR, Levy E: Phase II study of the bisphosphonate zoledronate in patients with osteolytic lesions. Proceedings of the Second International Conference on Cancer Induced Diseases. Davos, Switzerland: Second International Conference on Cancer Induced Diseases; 1999:39.
75. 75 Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.